Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report

Serena Vita; Alessandra D'Abramo; Andrea Coppola; Chiara Farroni; Anna Paola Iori; Francesca Faraglia; Alessandro Sette; Alba Grifoni; Cecilia Lindestam Arlehamn; Michele Bibas; Delia Goletti; Emanuele Nicastri

doi:10.3389/fonc.2024.1290614

Combined antiviral therapy as effective and feasible option in allogenic hematopoietic stem cell transplantation during SARS-COV-2 infection: a case report

Front Oncol. 2024 Feb 13:14:1290614. doi: 10.3389/fonc.2024.1290614. eCollection 2024.

Affiliations

¹ Clinical Department, National Institute for Infectious Diseases 'Lazzaro Spallanzani' Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy.
² Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
³ Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology (LJI), La Jolla, CA, United States.

Abstract

Here we describe the case of a 51 years old Italian woman with acute lymphoblastic leukemia who underwent to hematopoietic stem cell transplantation (HSCT) during SARS-COV-2 infection. She presented a prolonged COVID-19 successfully treated with dual anti SARS-COV-2 antiviral plus monoclonal antibody therapy.

Keywords: HSCT; SARS-CoV-2 infection; antigen-specific response; antivirals; dual antiviral therapy; immunocompromised; prolonged infection.

Publication types

Case Reports

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by Line 1 Ricerca Corrente “Studio dei patogeni ad alto impatto sociale: emergent, da importazione, multiresistenti, negletti” funded by Italian Ministry of Health, and 5 per Mille-Progetto 5M-2020-23682104.